I swear trading being part human and part bot goes in patterns...

I swear trading being part human and part bot goes in patterns like, buy on open being human seeing announcement and thinking wow this is undervalued. Once exhausted and human volume thins the bots come, and in this case push the price down with little resistance.

Short term trading is at the mercy of algorithms and profit taking.

I will post a share price current evaluation after the quarterly and revenue is more concrete, but at the moment we are looking at around 30c+ based on revenue alone (using P/S ratio), and close to 50c when adding in equity and FDA approval costs i.e. R&D investment. This is all before any FebriDx sales.